Republicans Have a Chance to Deliver for Millions of Sick Americans – Inside Sources

Right now, the Trump administration and Congress have an opportunity to seize on an issue that the last two Democratic administrations did not, and as we head into the 2026 midterm election cycle, the political incentive couldn’t be stronger.

In 2011, a woman named Courtney Miller stood up at a Barack Obama town hall in Reno, Nev., and asked the president why the federal government was essentially ignoring her husband — and millions of other Americans — living with a devastating disease called ME/CFS. Obama promised to ask the National Institutes of Health to do more. Advocates celebrated. It felt like a turning point.

That promise quickly disintegrated.

Soon after, funding for ME/CFS research fell to $5 million yearly — lower than before Obama made his promise. Under President Joe Biden, the disappointment continued as funding flatlined at $13 million annually, while long COVID — often linked to ME/CFS — was minting millions of new ME/CFS patients. Despite the National Institutes of Health approving a new research roadmap in 2024, the White House shelved it without a dollar to implement it.

Now Republicans are in the majority, and they have a choice: follow the same playbook of empty gestures, or actually deliver the funding needed to address this condition affecting millions of voters. This is one of the clearest political and moral opportunities this Congress has, and it would be foolish to let it pass, especially as we head into the 2026 midterm election cycle.

ME/CFS — Myalgic Encephalomyelitis/Chronic Fatigue Syndrome — is not what its name suggests. This is not burnout. This is not exhaustion. This is a serious, often devastating neurological disease, frequently triggered by a viral infection, that can strip people of their careers, their savings, and their ability to function. One in four patients is housebound or bedbound. There are zero FDA-approved treatments and no validated diagnostic test. And it affects up to 9 million Americans, more than multiple sclerosis and Parkinson’s disease combined.

Unlike Parkinson’s and multiple sclerosis, the federal government has all but ignored the condition, despite its effect on millions of Americans. That isn’t just a failure of leadership; it’s an economic failure.

ME/CFS costs the United States $362 billion annually in lost productivity and medical expenditures. Ninety-four percent of patients experience their professional lives disrupted. Twenty-two percent leave the workforce permanently. These are not statistics — they are voters. They are in every congressional district in this country, and so are their spouses, parents and children, who have quietly given up their own careers to care for someone the healthcare system failed.

What makes this moment different from every other is that for the first time in history, the federal government has an approved, expert-built research roadmap for ME/CFS. It was developed through a rigorous NIH process with scientists, clinicians and patients, and last year Congress directed NIH to implement it. NIH Director Jay Bhattacharya has called for prioritizing ME/CFS, the first NIH director to make such an explicit commitment.

The infrastructure is assembled. The plan is written. All that is missing is the $50 million needed to fund it. For members of Congress and the administration, this is the equivalent of a political home run, being served up on a platter.

The 2026 midterms are approaching, and the political landscape will be defined in part by whether this Congress delivered tangible results for Americans or spent its majority on abstractions. ME/CFS is one of the few issues that offers something genuinely rare: a bipartisan result with a clear, human story behind it, a ready-made plan, and an opportunity to deliver for millions of disenfranchised voters who have suffered in silence while its leaders have ignored them.

The administration has made it clear it wants to tackle the healthcare failures that Washington has ignored for too long. ME/CFS is the clearest possible test of whether that means something.

Germany has already committed 500 million euros to ME/CFS and long COVID research over the coming decade. Our allies are acting. American leadership in biomedical research — long the envy of the world — is not a birthright. It is something we either invest in or surrender.

There is a constituency waiting to be earned: 9 million Americans with ME/CFS, plus their families and caregivers — a community that has watched administration after administration make promises and walk away. Republicans who deliver here will have a story to tell that no Democrat can match, because no Democrat ever told it with money behind it.

Obama made a promise in Reno. Biden approved a roadmap and funded nothing. The voters remember.

This Congress and administration can be the one that actually acts. Not only is it the right thing to do for millions of Americans living with ME/CFS, but it is also the politically smart thing to do before millions of voters head to the polls.

Republicans have the opportunity to champion ME/CFS and give hope to those who need help most.